With Bernie Sanders' decisive win in New Hampshire, one fact is certain: The Democratic presidential candidate's plan for a single-payer healthcare system will remain in the spotlight.
Some states have denied Medicaid coverage for effective yet expensive hepatitis C drugs to patients and prisoners, and class-action lawsuits challenging those decisions could end up costing the states hundreds of millions of dollars, according to an article from The Pew Charitable Trusts.
The health insurance sector has seen a host of innovative startups recently, including broker services that tap into the rising trend of consumerism. But the controversy surrounding one such company also shows the challenges that tech-driven startups face in the highly regulated healthcare industry.
The vast majority of physicians and nurses report to work when they are sick in spite of the risk it poses to patients and other personnel. But it will take an institution-wide approach to stop the practice and encourage clinicians to stay home when they are ill, according to a study published in JAMA Pediatrics.
Presidential candidates on both sides of the aisle, including both winners of last night's New Hampshire primary, have supported allowing Medicare to negotiate drug prices. But a brief from the Kaiser Family Foundation says the financial windfall may be limited.
The Improving Health Information Technology Act and six other bills cleared the Senate health committee with bipartisan support at a hearing on Tuesday.
President Barack Obama unveiled his 2017 fiscal year budget Tuesday, including a host of provisions set to impact both public and private payers.
President Barack Obama will ask Congress for $1.8 billion in emergency funding to better prepare and respond to the Zika virus at home and abroad.
The government wants to take a more active role in selecting and designing health plans available on Healthcare.gov--similar to the approach California takes with its exchange.
The most recent guidelines from the U.S. Preventive Services Task Force recommend against routine testing for prostate-specific antigen, but the level to which this advice is followed may vary by physician type, according to a study published in JAMA Internal Medicine.